Literature DB >> 21471170

Postablation (131)I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer.

Renaud Ciappuccini1, Natacha Heutte, Géraldine Trzepla, Jean-Pierre Rame, Dominique Vaur, Nicolas Aide, Stéphane Bardet.   

Abstract

OBJECTIVE: Neck and thorax single photon emission computed tomography with computed tomography (SPECT-CT) improves the reliability of postablation (131)I whole-body scan (WBS) for differentiated thyroid cancer (DTC). The aim of this study was to assess the prognostic value for persistent or recurrent disease of postablation (131)I scintigraphy combining WBS and neck and thorax SPECT-CT with that of the previously known predictive factors.
METHODS: This is a single referral center prospective study with a median follow-up of 29 months. Postablation (131)I WBS and neck and thorax SPECT-CT were performed in 170 consecutive patients treated between 2006 and 2008. Stimulated serum thyroglobulin (Tg) and anti-thyroglobulin antibodies (TgAb) levels were measured. The impact on disease-free survival of age; gender; postablation (131)I scintigraphy; stimulated serum Tg level; T, N, and M status; and macroscopic lymph node involvement was assessed by univariate and multivariate analyses.
RESULTS: Persistent or recurrent disease was observed in 32 (19%) patients. In the whole group of patients, only positive WBS with SPECT-CT was related to an increased risk of persistent or recurrent disease (hazards ratio (HR)=65.21, 95% confidence interval (CI)=26.03-163.39, P<0.0001). In patients without TgAb (n=146), both positive WBS with SPECT-CT (HR=18.86, 95% CI=5.02-70.85, P<0.0001) and serum Tg level ≥58 ng/ml (HR=4.42, 95% CI=1.18-16.53, P=0.0271) were associated with an increased risk.
CONCLUSION: In patients with DTC, the cross analysis of postablation (131)I scintigraphy with neck and thorax SPECT-CT and stimulated serum Tg level enables early assessment of the risk of persistent or recurrent disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21471170     DOI: 10.1530/EJE-11-0156

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  17 in total

Review 1.  Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.

Authors:  Prasanna Santhanam; Lilja B Solnes; Steven P Rowe
Journal:  Med Oncol       Date:  2017-10-30       Impact factor: 3.064

2.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

Review 3.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

4.  2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer.

Authors:  L Leenhardt; M F Erdogan; L Hegedus; S J Mandel; R Paschke; T Rago; G Russ
Journal:  Eur Thyroid J       Date:  2013-09-05

Review 5.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

6.  RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system.

Authors:  Rebecca Zeuren; Agnese Biagini; Ravinder K Grewal; Gregory W Randolph; Dipti Kamani; Mona M Sabra; Ashok R Shaha; R Michael Tuttle
Journal:  Laryngoscope       Date:  2015-04-17       Impact factor: 3.325

Review 7.  Value of ¹³¹I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature.

Authors:  Yan-Li Xue; Zhong-Ling Qiu; Hong-Jun Song; Quan-Yong Luo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-15       Impact factor: 9.236

Review 8.  SPECT/CT in the Treatment of Differentiated Thyroid Cancer.

Authors:  Sang-Woo Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-02-08

9.  I-131 Postablation SPECT/CT Predicts Relapse of Papillary Thyroid Carcinoma more Accurately than Whole Body Scan.

Authors:  Julia V Malamitsi; John T Koutsikos; Stamatia I Giourgouli; Sophia F Zachaki; Theodoros A Pipikos; Fani J Vlachou; Vassilios K Prassopoulos
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

10.  Prognostic Value of Basal Serum Thyroglobulin Levels, but Not Basal Antithyroglobulin Antibody (TgAb) Levels, in Patients with Differentiated Thyroid Cancer.

Authors:  Isa Neshandar Asli; Ali Shafiepour Siahkali; Babak Shafie; Hamid Javadi; Majid Assadi
Journal:  Mol Imaging Radionucl Ther       Date:  2014-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.